PT - JOURNAL ARTICLE AU - Dennis Lapuente AU - Clara Maier AU - Pascal Irrgang AU - Julian Hübner AU - Sophia Peter AU - Markus Hoffmann AU - Armin Ensser AU - Katharina Ziegler AU - Thomas H. Winkler AU - Torsten Birkholz AU - Andreas E. Kremer AU - Philipp Steininger AU - Klaus Korn AU - Frank Neipel AU - Klaus Überla AU - Matthias Tenbusch TI - Rapid response flow cytometric assay for the detection of antibody responses to SARS-CoV-2 AID - 10.1101/2020.05.09.20091447 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.09.20091447 4099 - http://medrxiv.org/content/early/2020/05/13/2020.05.09.20091447.short 4100 - http://medrxiv.org/content/early/2020/05/13/2020.05.09.20091447.full AB - SARS-CoV-2 has emerged as a previously unknown zoonotic coronavirus that spread worldwide causing a serious pandemic. While reliable nucleic acid-based diagnostic assays were rapidly available, there exists only a limited number of validated serological assays. Here, we evaluated a novel flow cytometric approach based on antigen-expressing HEK 293T cells to assess spike-specific IgG and IgM antibody responses. Analyses of 201 pre-COVID-19 sera proved a high assay specificity in comparison to commercially available CLIA and ELISA systems, while also revealing the highest sensitivity in specimens from PCR-confirmed SARS-CoV-2 infected patients. Additionally, a soluble Angiotensin-Converting-Enzyme 2 (ACE-2) variant was established as external standard to quantify spike-specific antibody responses on different assay platforms. In conclusion, our newly established flow cytometric assay allows sensitive and quantitative detection of SARS-CoV-2-specific antibodies, which can be easily adopted in different laboratories and does not rely on external supply of assay kits.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the manuscript.